What is ArriVent BioPharma, Inc.'s accounts payable?

ArriVent BioPharma, Inc. (AVBP) reported accounts payable of $2.81M in Q1 2026.

How has ArriVent BioPharma, Inc.'s accounts payable changed year-over-year?

ArriVent BioPharma, Inc.'s accounts payable increased by 382.3% year-over-year, from $582K to $2.81M.

Roivant SciencesROIV

——

Operating income-$46.1M+30.9%

Net income-$43.3M+32.7%

EPS (diluted)-$0.96+49.5%

Cash & equivalents$62.1M+24.5%

Total debt$419.0K+204%

Total equity$324.0M+60.0%

Total assets$349.3M+62.1%

Operating cash flow-$41.9M+38.4%

Market cap$1.49B+62.1%

Enterprise value$1.43B+65.4%

Return on equity-55.2%+8.0pp

Debt / equity0×0.0×

Current ratio14×-0.4×

Reported directly by ArriVent BioPharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is ArriVent BioPharma, Inc.'s accounts payable?: ArriVent BioPharma, Inc. (AVBP) reported accounts payable of $2.81M in Q1 2026.
How has ArriVent BioPharma, Inc.'s accounts payable changed year-over-year?: ArriVent BioPharma, Inc.'s accounts payable increased by 382.3% year-over-year, from $582K to $2.81M.